Congenital Fibrinogen Deficiency in Hemophilia: A Review

dc.contributor.authorEmmanuel Ifeanyi Obeagu
dc.contributor.authorKeerthana Gnanavel
dc.date.accessioned2024-11-04T09:44:14Z
dc.date.available2024-11-04T09:44:14Z
dc.date.issued2022
dc.description.abstract000,000. It is an autosomal recessive disease caused by mutations in one of the three genes encoding the three polypeptide chains of fibrinogen located on the long arm of chromosome 4. Spontaneous bleeding, bleeding after minor trauma, and excessive bleeding during interventional procedures are the main symptoms. Replacement therapy is the mainstay of management of bleeding episodes in these patients, with plasma-derived fibrinogen concentrate being the drug of choice. Cryoprecipitate and fresh frozen plasma are alternative treatments that should only be used when fibrinogen concentrate is not available. Secondary preventive treatment can be considered after life-threatening bleeding, but primary preventive treatment is currently not recommended. We also discuss alternative treatment options and management of surgery, pregnancy, and thrombosis in these patients. New tests to identify at-risk patients and the development of safer replacement therapies will improve the treatment of afibrinogenemia in the future
dc.description.sponsorshipKampala International University
dc.identifier.issn2348-0319
dc.identifier.urihttp://hdl.handle.net/20.500.12493/14560
dc.language.isoen
dc.publisherInternational Journal of Innovative and Applied Research
dc.titleCongenital Fibrinogen Deficiency in Hemophilia: A Review
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
congenital-fibrinogen-deficiency-in-haemophillia-a-review.pdf
Size:
341.89 KB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: